In the preceding three months, 4 analysts have released ratings for CARISMA Therapeutics (NASDAQ:CARM), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 0 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $7.75, a high estimate of $9.00, and a low estimate of $6.00. A 22.5% drop is evident in the current average compared to the previous average price target of $10.00.
Investigating Analyst Ratings: An Elaborate Study
A clear picture of CARISMA Therapeutics...
Login or create a forever free account to read this news
Sign up/Log in